Ipsen pens early-stage, $14.5M programmed cell death cancer deal with BAKX Therapeutics

Ipsen pens early-stage, $14.5M programmed cell death cancer deal with BAKX Therapeutics
badams
Wed, 07/28/2021 – 09:00

Published on Wed, 28 Jul 2021 13:00:31 +0000 and brought to you by nintex array contains number